Cardiac Pharmacology: Difference between revisions

Jump to navigation Jump to search
no edit summary
No edit summary
No edit summary
Line 610: Line 610:
|Gastro-intestinal disturbances (2-20%)), taste disturbances, hepatic disturbances (up to 50%); bradycardia; pulmonary toxicity (1-17%); tremor (9-59%), sleep disorders; hypothyroidism (5-10%), hyperthyroidism (5-10%); reversible corneal microdeposits (up to 98%); phototoxicity, persistent slate-grey skin discoloration (1-7%), injection-site reactions; less commonly onset or worsening of arrhythmia, conduction disturbances, peripheral neuropathy (1-105) and myopathy; very rarely sinus arrest, bronchospasm, ataxia (2-37%), benign intracranial hypertension, headache, vertigo, epididymo-orchitis, impotence, haemolytic or aplastic anaemia, thrombocytopenia, rash, hypersensitivity including photosensitivity (2-20%), anaphylaxis on rapid injection, hypotension (10-30%), respiratory distress syndrome, sweating, and hot flushes
|Gastro-intestinal disturbances (2-20%)), taste disturbances, hepatic disturbances (up to 50%); bradycardia; pulmonary toxicity (1-17%); tremor (9-59%), sleep disorders; hypothyroidism (5-10%), hyperthyroidism (5-10%); reversible corneal microdeposits (up to 98%); phototoxicity, persistent slate-grey skin discoloration (1-7%), injection-site reactions; less commonly onset or worsening of arrhythmia, conduction disturbances, peripheral neuropathy (1-105) and myopathy; very rarely sinus arrest, bronchospasm, ataxia (2-37%), benign intracranial hypertension, headache, vertigo, epididymo-orchitis, impotence, haemolytic or aplastic anaemia, thrombocytopenia, rash, hypersensitivity including photosensitivity (2-20%), anaphylaxis on rapid injection, hypotension (10-30%), respiratory distress syndrome, sweating, and hot flushes
|-
|-
|
|Class IV (Calcium channel blockers)
|Class IV (Calcium channel blockers)
|(See above)
|(See above)
|(See above)
|(See above)
|(See above)
|(See above)
|
|(See above)
|(See above)
|-
|-
Line 627: Line 629:
AVRT, poorly tolerated: Class IIIC
AVRT, poorly tolerated: Class IIIC
Since or infrequent AVRT episode(s): Class IIIC
Since or infrequent AVRT episode(s): Class IIIC
Prophylaxis of SVT during pregnancy: Class IC |Gastro-intestinal disturbances (vomiting, diarrhoea, anorexia, abdominal pain) (25%); arrhythmias (up to 50%), AV conduction disturbances (50%); nervous system disturbances (dizziness, apathy, confusion, headache, fatigue, weakness) (25%); blurred or yellow vision; rash, eosinophilia, depression, anorexia, intestinal ischaemia and necrosis, psychosis, gynaecomastia on long-term use, and thrombocytopenia
Prophylaxis of SVT during pregnancy: Class IC
|Gastro-intestinal disturbances (vomiting, diarrhoea, anorexia, abdominal pain) (25%); arrhythmias (up to 50%), AV conduction disturbances (50%); nervous system disturbances (dizziness, apathy, confusion, headache, fatigue, weakness) (25%); blurred or yellow vision; rash, eosinophilia, depression, anorexia, intestinal ischaemia and necrosis, psychosis, gynaecomastia on long-term use, and thrombocytopenia
|-
|-
|
|
Line 638: Line 641:
Symptomatic (NYHA class II-IV) HF: Class IIbB
Symptomatic (NYHA class II-IV) HF: Class IIbB
ESC Guidelines Symptomatic (NYHA class II-IV) HF, LVD and AF: Class IB
ESC Guidelines Symptomatic (NYHA class II-IV) HF, LVD and AF: Class IB
Acute HF with AF and VT: Class IC
Acute HF with AF and VT: Class IC
|
|-
|-
|Anti-platelet Drugs
|Anti-platelet Drugs
Line 671: Line 675:
|
|
|-
|-
|
|
|
|Clopidogrel
|Clopidogrel
|Prevention of thrombotic events (esp. when warfarin not tolerated)
|Prevention of thrombotic events (esp. when warfarin not tolerated)
467

edits

Navigation menu